Amylyx’s ALS Drug Should Wait For Phase III Results, US FDA Panel Says

Six of 10 advisory committee members say Phase II CENTAUR trial cannot stand on its own to support approval at this time. However, patients and advocates say thousands will die if they have to wait for the Phase III PHOENIX trial to complete in 2024 before the drug becomes widely available.

Bird on one leg
This bird may be able to stand on one leg, but Amylyx's ALS drug cannot, an FDA committee said. • Source: Alamy

The US Food and Drug Administration should wait for results from an ongoing Phase III trial of Amylyx Pharmaceuticals, Inc.’s AMX0035 before approving the amyotrophic lateral sclerosis drug, a slim advisory committee majority said on 30 March.

However, the split nature of the vote, and the extensive and vociferous patient community testimony in support of approval during...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers